SEC Form 4 · accession 0000904454-17-000345
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kim P. Kamdar
Director · 10% Owner
Period of report
May 11, 2017
Accepted (ET)
May 15, 2017 · 5:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.15 | May 11, 2017 | A | 63,500 | A | — | May 11, 2027 | Common Stock | 63,500 | 63,500 | D |
Explanation of responses
- F1The option vests monthly over a one-year period beginning on 2/15/2017, and will fully accelerate upon a change of control of the Issuer.